Bahija Jallal

Pharmacogenomics
Vice-President
MedImmune
United Kingdom

Business Expert Pathology
Biography

  Bahija also serves on the Board of Trustees of the Johns Hopkins University in Baltimore, Maryland. Bahija received a master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Research Intrest

  Bahija joined MedImmune as Vice-President, Translational Sciences in 2006. She has guided the MedImmune R&D organisation through unprecedented expansion of its pipeline from 40 drugs to more than 120. Biologics now makes up 50% of AstraZeneca’s pipeline. Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science